[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.120.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
January 7, 1998

Warning on Use of Terbutaline Sulfate for Preterm Labor

Author Affiliations
 

Not Available

Not Available

JAMA. 1998;279(1):9. doi:10.1001/jama.279.1.9-JFD71011-2-1

The FDA is alerting physicians and other health professionals to concerns about subcutaneous administration of terbutaline sulfate via infusion pump for off-label use as treatment and prevention of preterm labor (tocolytic therapy). Terbutaline sulfate is approved only for the treatment of asthma, and the approved labeling for terbutaline sulfate injection states that the drug should not be used for the management of preterm labor. The only drug currently approved for tocolytic therapy is ritodrine hydrochloride injection.

First Page Preview View Large
First page PDF preview
First page PDF preview
×